Biotron Limited · ASX:BIT
Biotron — Investor Presentation (October 2021)
13 slides from Biotron's investor presentation, October 2021
Slide 1: Biotron Limited Investor Presentation October 2021
BIOTRON LIMITED (ASX:BIT) Investor Presentation October 2021
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are statements t
Slide 3: Biotron Overview
Biotron Overview • Clinical stage company developing small molecule drugs targeting viral diseases with major health problems: • HIV-1 , COVID-19, Hepatitis B virus and others • Unique approach to tackling virus infections • Combining direct antiviral and immunomodulatory activities to knock down vi
Slide 4: Biotron's Core Technology/Expertise
Biotron’s Core Technology/Expertise • Targeting a key viral protein class found on a range of different viruses • Known as viroporins – these proteins determine how efficiently a virus infects cells and evades the immune system • The HIV-1 program, including a successful, completed, Phase 2 HIV-1 cl
Slide 5: SARS-CoV-2 – E Protein
SARS-CoV-2 – E Protein • Biotron’s approach has been to design new small molecule drugs that target the SARS-CoV-2 viroporin(s) • E protein is a viroporin • Multiple roles in the virus lifecycle • Entry into cells and exit of new virus particles from infected cells • Pathogenesis of disease resultin
Slide 6: SARS-CoV-2 Program
SARS-CoV-2 Program Vaccines remain central to control of the pandemic but there is an urgent need for effective drugs to treat COVID in at-risk populations Dose-Response Curves – BITCoV vs remdesivir • Designed and synthesised >100 new compounds to target the SARS-CoV-2 E BITCoV Plaque Assay SARS-Co
Slide 7: HIV-1 Unmet Need
HIV-1 Unmet Need • Safe, effective antiretroviral drugs (ART) have been central to successfully keeping virus levels down in HIV+ people; Profound reductions in mortality, morbidly and transmission BUT • ART is not curative, latent viral reservoirs remain and reactivate • Immune reconstitution is on
Slide 8: BIT225 – A new class of anti-HIV drug
BIT225 – A new class of anti-HIV drug • BIT225 is a first-in-class drug that uniquely combines direct acting antiviral with immunomodulatory activities. • BIT225 targets Vpu protein of HIV-1 • Vpu is responsible for down-regulating key receptors on infected cells so that infected cells are hidden fr
Slide 9: Next Steps for BIT225
Next Steps for BIT225 • Two new trials are currently before Ethics committees (Australia/Thailand) to further explore key observations related to inflammation and immune activation in both treatment naïve and experienced populations • Assessing key biomarkers (immunological and virological) consiste
Slide 10: Summary
Summary • HIV-1 program is the prime focus • Clear clinical development program designed to demonstrate to regulators and pharma how the drug may be used to improve health outcomes in combination with ART • We have several promising SARS-CoV-2 drugs in preclinical development with potential to impac
Slide 11: Outlook for 2021/22 FY
Outlook for 2021/22 FY • 2H2021 • Commencement of two HIV-1 trials following receipt of ethics/regulatory approvals • Results from testing BITCoV in animal model of SARS-CoV-2 infection • Results from cell-based immunomodulatory studies • Results from testing BITHBV in animal model of Hepatitis B vi
Slide 12: Financial Information
Financial Information Key Financial Metrics Ticker Code ASX: BIT Share Price (21/09/21) A $0.050 Market Cap A $35 million 12 Month Trading Range A $0.046 – 0.105 Shares Outstanding 702 million Cash Position (06/2021) A $4.21 million Board Michael Hoy Non-executive Chairman Michelle Miller Managing D
Slide 13: Biotron Limited
BIOTRON LIMITED (ASX:BIT) Michelle Miller Managing Director mmiller@biotron.com.au www.biotron.com.au +61 412313329